6RK73 |
| Katalog-Nr.GC39625 |
6RK73 ist ein kovalenter irreversibler und spezifischer UCHL1-Inhibitor mit einem IC50 von 0,23 μM. 6RK73 zeigt fast keine Hemmung von UCHL3 (IC50 = 236 μM). 6RK73 hemmt spezifisch die UCHL1-AktivitÄt bei Brustkrebs.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1895050-66-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer[1].
[1]. Liu S, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis. Clin Cancer Res. 2019 Dec 19. pii: clincanres.1373.2019.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *